• We are available for your help 24/7
  • Email: info@isindexing.com, submission@isindexing.com

Paper Details


Ramchandra N. Chilkawar*, S. M. Patil, Dr. B. K. Nanjwade, V. S. Panchal

Journal Title:World Journal of Pharmaceutical Research

Glibenclamide (Glyburide) is a potent oral antidiabetic agent and orally active second generation sulphonyl urea used in lowering bloodglucose in patients with type II diabetes mellitus (NIDDM). Glibenclamide has short half life of 4-6 hours. The objective of this study is Development and evaluation of colloidosomes of Glibenclamide for controlled/sustained drug release. An attempt was made to formulate and evaluate colloidosomes of Glibenclamide as a model drug using oil in water emulsion based method by using CaCO3 as a colloidal particle with a view to deliver drug at controlled/ sustained manner in GIT and consequently into systemic circulation. The prepared colloidosomes were evaluated for particle size, shape and surface morphology, FTIR study, DSC, XRD, % yield, % drug entrapment efficiency, Zeta potential, In-vitro drug release studies. The release rates were studied using GRAPHPAD PRISM software. The obtained Colloidosomes were found to be discrete and spherical in shape and had mean particle size range of 45 m -115.14m, drug entrapment efficiency was found to be 65.88 % to 76.28% All the colloidosomes formulations were stable and good sustained release of the drug for a period of 8 hours. The release profile was very promising as compar ed with marketed formulation and followed Zero order kinetic Model. This implies that developed formulations have a potential to deliver the drug in controlled release manner. This outcome from release profiling strongly recommends that developed Glibenclamide loaded colloidosomes can be useful delivery carrier to deliver drug in controlled release manner which is a prime requirement for the treatment of type II Diabetes mellitus (NIDDM).